Drug Database
CA

carbetocin (Lonactene / Duratocin / Pabal)

✓ Approved

Ferring · OXTR · Small Molecule

What is carbetocin?

carbetocin is a small molecule developed by Ferring. It is approved for therapeutic indications via injectable (others) or intravenous (iv).

Drug Profile

Brand NamesLonactene, Duratocin, Pabal
CompanyFerring
Drug ClassSmall Molecule
Molecular TargetOXTR
RouteInjectable (Others), Intravenous (IV)
StatusApproved

Mechanism of Action

Molecular Targets

carbetocin acts on 1 molecular target:

OXTRoxytocin receptor (OTR, OT-R)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

carbetocin is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Pregnancy, puerperium and perinatal conditionsPostpartum haemorrhage✓ Approved

Related Research Articles

PubMedHealthcare (Basel, Switzerland)2026-08-13

Five-Year Trends in Obstetric Hemorrhage, Hemostatic Management, and Blood Product Utilization at a Tertiary Maternity Center in Kazakhstan: A Retrospective Time-Series Study.

Ayazbekov Ardak A, Kurmanova Almagul A, Khaidarov Saken S, Terlikbayeva Aigul A et al.

Background/Objectives: Obstetric hemorrhage remains a leading cause of maternal morbidity and mortality. We examined five-year institutional trends in the recorded hemorrhage rate, cesarean delivery, uterus-preserving hemostatic procedures, uterotonic and antifibrinolytic use, and blood product consumption at a high-volume tertiary maternity center in Kazakhstan. Methods: This was a retrospective time-series analysis of aggregated annual and monthly records for 2018-2022 (46,554 deliveries). The outcome was hemorrhage as entered on the hemorrhage line of the institutional register against the national threshold of 500 mL after vaginal birth and 1000 mL after cesarean; measured blood loss and severity grade were not recorded, so the study describes incidence rather than severity, and blood product figures are hospital-wide adult transfusion volumes. We calculated rates per 1000 deliveries with Wilson confidence intervals, fitted Poisson regression with delivery volume as an offset to estimate incidence rate ratios (IRRs), compared recorded hemorrhage by delivery route with Fisher's exact test, screened for seasonality and out-of-limit months with process control charts, and correlated the monthly hemorrhage rate with service-use variables before and after detrending, with false-discovery-rate correction. Results: The recorded hemorrhage rate fell from 11.39 to 3.62 per 1000 deliveries (rate ratio 0.318, 95% CI 0.217-0.466; 68.2% relative reduction), an average decline of 27.6% per year (IRR 0.724, 95% CI 0.665-0.788, p < 0.001). No reproducible seasonal pattern was found. The cesarean rate declined from 24.90% to 19.36%. Carbetocin and tranexamic acid use rose several-fold, while red cell volume per delivery fell by about 48%. Raw inverse correlations between medication use and hemorrhage were explained by the shared time trend and did not survive detrending and correction. Conclusions: The center recorded a substantial, statistically robust decline in recorded obstetric hemorrhage alongside expanded pharmacologic prophylaxis and reduced transfusion. Because the data are aggregate and neither placental pathology nor other patient case mix could be measured, the parallel trends cannot show that any intervention caused the fall, and a shift in documentation practice cannot be excluded. The findings support prospective monitoring and patient-level study. Because severe hemorrhage and the surgery used to control it may compromise later fertility, the reproductive outcomes of these women are a priority for further research.

PubMedNigerian medical journal : journal of the Nigeria Medical Association2026-08-05

A Comparative Study on Oxytocin Versus Carbetocin in Prevention of Primary Postpartum Haemorrhage After Childbirth.

Dasghosh Anwesha A, Datta Subhra Kanti SK, Brahma Rupa R

Postpartum haemorrhage (PPH) remains a leading cause of maternal morbidity and mortality worldwide. Effective prophylactic uterotonic agents are essential for preventing primary PPH after childbirth. The study aims to compare the effectiveness and safety of oxytocin versus Carbetocin in preventing primary PPH following both vaginal and caesarean deliveries in a tertiary care setting in Eastern India. This prospective, open-label, randomized controlled superiority trial was conducted over 18 months (October 2022-March 2024) at B.R. Singh Hospital, Kolkata. One hundred and twenty pregnant women aged 18-35 years with singleton pregnancies ≥37 weeks undergoing normal vaginal delivery or caesarean section were randomized into two groups. The Oxytocin group (n=60) received 10 IU intravenously with a maintenance dose, while the Carbetocin group (n=60) received 100μg intravenously without a maintenance dose. Primary outcomes included total blood loss and incidence of PPH. Secondary outcomes included uterine atony and additional uterotonic requirements, hemodynamic changes, change in hemoglobin levels, and maternal side effects. Carbetocin significantly reduced total blood loss in both delivery modes (p<0.001). PPH incidence was lower with Carbetocin (17.9% vs 29.6% in caesarean delivery; 9.4% vs 27.3% in vaginal delivery). Post-delivery haemoglobin levels were significantly higher, and haemoglobin drop was significantly lower in the Carbetocin group. Uterine atony occurred less frequently with Carbetocin (23.3% vs 43.3%, p<0.05). Carbetocin caused minimal hemodynamic changes compared to the significant hypotensive effects of oxytocin. Carbetocin is superior to oxytocin in preventing primary PPH, offering better efficacy and safety profile through reduced complications.

PubMedCureus2026-08-02

The Prophylactic Role of Tranexamic Acid in Reducing Blood Loss During Cesarean Delivery: A Prospective Randomized Controlled Trial.

Shree Pragya P, Gupta Roshani R, Sachan Divyata D, Verma Vandana V et al.

Postpartum hemorrhage (PPH) is a major risk associated with cesarean delivery. This randomized controlled trial (RCT) aimed to evaluate the prophylactic role of intravenous tranexamic acid (TXA) in reducing total intraoperative blood loss in women undergoing lower-segment cesarean section (LSCS). The study was conducted at the Autonomous State Medical College, Fatehpur, from September 1, 2024, to March 31, 2025. The primary aim of the trial was to investigate the effect of TXA on perioperative and postoperative blood loss during cesarean section in a low-resource setting. A simple randomization technique was used to allocate 300 participants to either group in a 1:1 ratio. The median estimated blood loss (EBL) was identical in both groups at 450 mL (IQR, 250-1000 mL), as measured by the gravimetric method. The mean EBL was lower in the TXA group (460.33 mL) than in the placebo group (511.93 mL) (p < 0.05). The mean changes in hemoglobin level and packed cell volume (PCV) were similar between the two groups. There was no statistically significant difference between the groups in the need for additional uterotonics (misoprostol, carboprost, or carbetocin). Blood transfusions were required in 4.7% (7 cases) of the TXA group and 9.3% (14 cases) of the placebo group. Gastrointestinal side effects were reported in 42.0% of the TXA group and 37.3% of the placebo group. No thromboembolic events were reported in either group. The mean birth weight and mean APGAR scores at one minute were comparable between the two groups. This study supports the prophylactic use of TXA during cesarean delivery to reduce intraoperative blood loss. The significant reduction in mean EBL, combined with the absence of major adverse effects, underscores the role of TXA as a safe and effective adjunct to standard uterotonic therapy.

PubMedClinical therapeutics2026-07-23

Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome: Results From the Randomized, Placebo-Controlled, Phase 3 Compass PWS Study.

Roof Elizabeth E, Strong Theresa V TV, Stafford Diane E J DEJ, Singh Deepan D et al.

Prader-Willi syndrome (PWS) is a rare genetic disorder characterized by endocrine and neuropsychiatric problems including hyperphagia, anxiousness, and distress. The oxytocinergic system represents one of the key neural circuits that is dysfunctional in PWS, making it an attractive therapeutic target. The oxytocin analog carbetocin has a longer half-life and greater receptor selectivity than oxytocin and showed therapeutic potential in the phase 3 CARE-PWS study (ClinicalTrials.gov NCT03649477) based on nominally significant improvements in hyperphagia and anxiousness with the 3 times daily (TID) 3.2-mg dose of intranasal carbetocin over placebo. The phase 3 placebo-controlled COMPASS PWS study was conducted to confirm the potential benefit observed with carbetocin in the CARE-PWS study. In the 12-week COMPASS PWS study (ClinicalTrials.gov NCT06173531), 175 participants were randomized 1:1 to carbetocin 3.2 mg TID nasal spray (n = 85) and placebo (n = 90). The primary efficacy endpoint was the change from baseline at week 12 in the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) score. Secondary efficacy endpoints were the change in the Clinical Global Impression-Severity (CGI-S) score for PWS, and in the CGI-S for hyperphagia in PWS score from baseline at week 12, the CGI-Change for PWS score at week 12, and the percentage of participants with a treatment response (defined as improvement from baseline ≥8 points) based on the HQ-CT at week 12. Exploratory efficacy endpoints included the change from baseline at week 12 in scores for the PWS Anxiousness and Distress Behaviors Questionnaire. The least squares mean change (standard error) from baseline at week 12 in the HQ-CT was -4.8 (0.8) and -5.1 (0.8) in the carbetocin and placebo groups, respectively; the treatment difference of 0.3 (95% confidence interval: -1.8, 2.4; P = 0.79) was not statistically significant. There was no separation between carbetocin and placebo for any secondary or exploratory endpoint. The most frequently reported treatment-emergent adverse events in the carbetocin-treated participants were headache (n = 6 [7.2%]) and pyrexia (n = 5 [6.0%]). Carbetocin nasal spray did not demonstrate efficacy compared with placebo for hyperphagia in PWS in the 12-week COMPASS PWS study.

PubMedMaternal-fetal medicine (Wolters Kluwer Health, Inc.)2026-07-22

Carbetocin in the Prevention of Postpartum Hemorrhage after Vaginal Birth: A Systematic Review and Meta-Analysis.

El-Goly Nour A NA, Maged Ahmed M AM, Shamel Ahmed A, El-Sherbiny Wael W

To evaluate the safety and efficacy of carbetocin for reducing blood loss following vaginal delivery (VD). Databases, including MEDLINE, Scopus, Web of Science, EMBASE, Cochrane Library, Scopus, and clinical trial registries, were screened from inception to November 2024 using keywords related to carbetocin, postpartum hemorrhage (PPH), postpartum blood loss, and VD. Only randomized controlled trials included participants who underwent VD, totaling 19 studies including 69,884 women. Seventeen studies were published in English, one in Spanish, and one in Chinese. The extracted data included study location, number of participants and characteristics, intervention (including dose, route, and timing of administration), primary and secondary outcome parameters, and trial registration details. Thirteen studies with 64,731 participants compared carbetocin to oxytocin. Blood loss in the first 24 h was assessed in ten trials (7403 participants), which reported a mean difference (MD) of -28.13 mL (95% confidence interval (CI): -51.76, -4.50; P = 0.020). The difference between antepartum and postpartum hemoglobin levels was measured in seven trials (2737 participants), which reported an MD of -0.39 g/dl (95% CI: -0.48, -0.29; P < 0.001). PPH > 500 mL and severe PPH > 1000 mL were reported in ten and seven studies (64,416 and 63,789 participants, respectively), with odds ratios (ORs) of 0.99 (95% CI: 0.89, 1.10; P = 0.800) and 0.98 (95% CI: 0.89, 1.09; P = 0.720), respectively. The need for additional uterotonics was assessed in ten trials (34,852 participants), with an OR of 0.67 (95% CI: 0.49, 0.90; P = 0.008). Six studies (10,145 participants) compared carbetocin to syntometrine. Blood loss in the first 24 h was assessed in five trials (4853 participants), which reported an MD of -35.29 mL (95% CI: -75.68, 5.09; P = 0.090). The difference between the antepartum and postpartum hemoglobin levels was measured in four trials (860 participants), which reported an MD of -0.29 g/dl (95% CI: -0.48, -0.09; P = 0.004). PPH > 500 mL and severe PPH > 1000 mL were reported in five and four studies (4835 and 4733 participants, respectively), with ORs of 1.09 (95% CI: 0.96, 1.24; P = 0.170) and 0.93 (95% CI: 0.78, 1.09; P = 0.360), respectively. The need for additional uterotonics was calculated in five trials (4933 participants), with an OR of 0.93 (95% CI: 0.60, 1.46; P = 0.770). Carbetocin administration was associated with reduced blood loss during the first 24 h after VD, a less severe decrease in postpartum hemoglobin levels, and a reduced need for additional uterotonics compared with oxytocin administration. Registration number CRD42023492407.

PubMedBMC pregnancy and childbirth2026-07-21

Prevention and management of postpartum hemorrhage and hypertensive disorders of pregnancy: results from a 31-country rapid assessment.

Sharma Gaurav G, Noriega Angeline A, Somji Aleefia A, Blockett Andre A et al.

Postpartum hemorrhage (PPH) and Hypertensive Disorders of Pregnancy (HDP) remain leading causes of maternal death. This multi-country survey asked key informants to assess uptake of evidence-based practices; determine their country's implementation of updated WHO global guidelines; and describe the private sector's role in PPH and HDP management. To our knowledge, this is among the few multi-country assessments to examine national implementation of updated WHO recommendations for PPH and HDP alongside private-sector engagement across three major regions-sub-Saharan Africa, South and Southeast Asia, and Latin America and the Caribbean-providing a comparative view to guide advocacy and programme planning. From January to May 2022, 35 countries in sub-Saharan Africa, South and Southeast Asia, and Latin America and the Caribbean were invited to complete a survey (based on 2011 and 2012 surveys) on PPH and HDP management across public and private sectors on PPH and HDP management. Using purposive sampling, country-based focal persons assembled national expert teams from public and private sectors in health policy, education, procurement/distribution, logistics, and information systems to complete the survey. Teams produced consensus-based answers by reviewing nationally available data and policy documents. The Study Team developed composite scores for key quantitative indicators and thematically analyzed qualitative data. Thirty-one countries completed the survey. Despite significant progress since 2012, several gaps remain. Oxytocin was reported as regularly available in public facilities by 77% of countries and in private facilities by 84% of countries. Magnesium sulfate was reported as available in public facilities by 58% of countries and in private facilities by 45% of countries. Interventions like umbilical vein injection of oxytocin for retained placenta (13% of countries) and heat-stable carbetocin for PPH prevention (45% of countries) were less integrated in national policy guidelines. Since 2011, midwifery scope of practice remained stagnant for manual removal of placenta for PPH, diagnosing severe pre-eclampsia/eclampsia, and giving the loading dose of MgSO4, but 60% of countries in 2022 reported that newer PPH treatments (such as tranexamic acid) were included. Quality assurance systems for procurement of essential drugs and data reporting into national information systems were deficient, particularly in the private sector. Recommendations include prioritizing integration of updated global guidelines; improving uptake through professional education, mentorship, and supervision; quality assurance; strengthening procurement and supply chains to improve access, availability, and quality of essential drugs and commodities; expanding midwives' scope of practice; and improving private sector governance to enhance reporting of important MNH indicators.

+411 more articles available with a free account

Sign up free to view all articles →

Ask about carbetocin